Advertisement

Clozapine attenuates meta-chlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia

  • Alan Breier
    Correspondence
    Address reprint requests to Alan Breier, MD, Experimental Therapeutics Branch, NIMH, Bldg. 10, Room 4N214, 9000 Rockville Pike, Bethesda, MD 20892.
    Affiliations
    From the Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA

    Experimental Therapeutics Branch, National Institute of Mental Health, Bethesda, MD, USA
    Search for articles by this author
  • Brian Kirkpatrick
    Affiliations
    Experimental Therapeutics Branch, National Institute of Mental Health, Bethesda, MD, USA
    Search for articles by this author
  • Robert W. Buchanan
    Affiliations
    Experimental Therapeutics Branch, National Institute of Mental Health, Bethesda, MD, USA
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Abraham G.E.
        • Buster J.E.
        • Teller R.C.
        Radioimmunoassay of plasma cortisol.
        Ann Lett. 1972; 5: 757-766
        • Altar C.A.
        • Wasley A.M.
        • Neale R.F.
        • Stone G.A.
        Typical and atypical antipsychotic occupancy of D2 and S2 receptors: An autoradiographic analysis in rat brain.
        Brain Res Bull. 1986; 16: 517-527
        • Canton H.
        • Verriele L.
        • Colpaert F.C.
        Binding of typical and atypical antipsychotics to 5-HT1c and 5-HT2 sites: clozapine potently interacts with 5-HT1c sites.
        Eur J Pharmacol. 1990; 191: 93-96
        • Conn P.J.
        • Sanders-Bush E.
        Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1C) receptors.
        J Pharmacol Exp Ther. 1987; 242: 552-557
        • Hoyer D.
        Functional correlates of serotonin 5-HT1 recognition sites.
        J Recept Res. 1988; 8: 49-81
        • Iqbal N.
        • Asnis G.M.
        • Wtzler S.
        • Khan R.S.
        • Kay S.R.
        • van Praag H.M.
        The MCPP challenge test in schizophrenia; hormonal and behavioral responses.
        Biol Psychiatry. 1991; 30: 770-778
        • Kahn R.S.
        • Davidson M.
        • Siever L.
        • Stern R.G.
        • Azueta R.
        • Davis K.L.
        Indices of serotonin, dopamine and norepinephrine function and treatment response to clozapine in schizophrenic patients.
        American College of Neuropsychopharmacology 1992 Abstracts. 1992;
        • Kane J.
        • Honigfeld G.
        • Singer J.
        • Meltzer H.
        • Clozaril Collaborative Study Group
        Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine.
        Arch Gen Psychiatry. 1988; 45: 789-796
        • Krystal J.H.
        • Seibyl J.P.
        • Karper L.
        • et al.
        Clozapine versus haloperidol blockade of M-CCP in schizophrenia.
        American Psychiatric Association 1992 New Research Program and Abstracts. 1992;
        • Krystal J.H.
        • Seibyl J.P.
        • Price L.H.
        • et al.
        m-Chlorophenylpiperazine (MCPP) effects in neuroleptic-free schizophrenic patients: evidence implicating serotonergic systems in the positive symptoms of schizophrenia.
        Arch Gen Psychiatry. 1993; 50: 624-635
        • Meltzer H.Y.
        • Bernett S.
        • Bastani B.
        • Ramirez L.F.
        Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients.
        Hosp Community Psychiatry. 1990; 41: 892-897
        • Owen Jr., R.R.
        • Gutierrez-Esteinou R.
        • Hsiao J.
        • et al.
        Effects of clozapine and fluphenazine treatment on responses to m-Chlorophenylpiperazine (m-CPP) infusions in schizophrenia.
        Arch Gen Psychiatry. 1993; 50: 636-644
        • Pickar D.
        • Owen R.R.
        • Litman R.E.
        • Konicki P.E.
        • Gutierrez R.
        • Rapaport M.H.
        Clinical and biological response to clozapine in patients with schizophrenia: Crossover comparison with fluphenazine.
        Arch Gen Psychiatry. 1992; 49: 345-353
        • Spitzer R.L.
        • Williams J.B.W.
        • Gibbon M.
        • First M.B.
        Structured Clinical Interview for DSM-III-R.
        Biometrics Research Department, New York State Psychiatric Institute, New York1989
        • Wander T.J.
        • Nelson A.
        • Okazaki H.
        • Richelson E.
        Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro.
        Eur J Pharmacol. 1987; 143: 279-282